Skip to main content
SpringerLink
Log in

Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance

  • Original Articles
  • Fostriecin, Drug Resistance, Topoisomerase, Small-Cell Lung Carcinoma
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Cells exhibiting decreased topoisomerase II (Topo II) activity are resistant to several drugs that require Topo II as an intermediate. These drugs are cytotoxic due to the formation of a cleavable complex between the drug, Topo II and DNA. Fostriecin belongs to a new class of drugs that inhibit Topo II without inducing the formation of this cleavable complex. We tested fostriecin in three human small-cell lung carcinoma cell lines. GLC4 is the parent line. GLC4/ADR is the P-glycoprotein-negative multidrug-resistant subline, which is resistant to several Topo II inhibitors due to its decreased Topo II activity. GLC4/cDDP is the cisplatin-resistant subline, which displays increased Topo II activity. Topo II activity proved to be 100% in GLC4, 35% in GLC4/ADR and 130% in GLC4/cDDP. The fostriecin concentration causing inhibition of the growth of 50% of the cells (IC50) in the microculture tetrazolium assay following continous incubation was 11.2, 4.1 and 14.9 μm, respectively. After 1-h incubations, the IC50 was 117.8, 101.3 and 219.8 μm, respectively. Our results indicate a relationship between Topo II activity and fostriecin sensitivity in these closely related cell lines. At least in vitro, fostriecin displayed the capacity to kill cells showing resistance to drugs due to decreased Topo II activity. There was no relationship between this capacity and an increase in the activity of the reduced-folate carrier system, the proposed machanism for cellular entry of fostriecin, since we found no correlation between the cytotoxity of fostriecin and that of methotrexate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alexander RB, Nelson WG, Coffey DS (1987) Synergetic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 47: 2403

    Google Scholar 

  2. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW (1988) Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063

    Google Scholar 

  3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 72: 248

    Google Scholar 

  4. Curt GA, Clendeninn NJ, Chabner BA (1984) Drug resistance in cancer. Cancer Treat Rep 81: 87

    Google Scholar 

  5. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by topoisomerase II from human leukemic cells selected for resistance to VM26. Biochemistry 27: 8861

    Google Scholar 

  6. Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and-resistant P388 leukemia cell lines. Cancer Res 49: 58

    Google Scholar 

  7. Drake FH, Hofmann GA, Mong SM, O'Leary Bartus J, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578

    Google Scholar 

  8. Epstein RJ, Smith PJ (1988) Estrogen-induced potentiation of DNA-damage and cytotoxicity in human breast cancer cells treated with topoisomerase II interactive antitumor drugs. Cancer Res 48: 297

    Google Scholar 

  9. Ferguson PJ, Fisher MH, Stephenson J, Li D, Zhou B, Cheng Y (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956

    Google Scholar 

  10. Fry DW, Besserer JA, Boritzki TJ (1984) Transport of the antitumor antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 44: 3366

    Google Scholar 

  11. Holm C, Goto T, Wang JC, Botstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553

    Google Scholar 

  12. Hospers GAP, Mulder NH, Jong B de, Ley L de, Uges DRA, Fichtinger-Schepman AMF, Scheper RJ, Vries EGE de (1988) Characterization of a human small cell lung carcinoma cell line with acquired cisplatin resistance in vitro. Cancer Res 48: 6803

    Google Scholar 

  13. Jong S de, Zijlstra JG, Vries EGE de, Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in extracts from an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304

    Google Scholar 

  14. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC (1984) Anticancer activity of the structurally novel antibiotic CI-920 and its analogs. Cancer Res 44: 1928

    Google Scholar 

  15. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351

    Google Scholar 

  16. Long BH, Wang L, Lorico A, Brattain MG, Casazza AM (1985) Mechanisms of resistance to etoposide (VP16) and teniposide (VM26) in acquired resistant human colon and lung carcinoma cell lines. Proc Am Assoc Cancer Res 30: 2017

    Google Scholar 

  17. Morrow CS, Cowan KH (1988) Mechanisms and clinical significance of multidrug resistance. Oncology 2: 55

    Google Scholar 

  18. Moscow JA, Cowan KH (1988) Multidrug resistance. J Natl Cancer Inst 80: 14

    Google Scholar 

  19. Osheroff N (1989) Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 41: 223

    Google Scholar 

  20. Ross WE, Sullivan DM, Chow KC (1988) Altered function of DNA topoisomerases as a basis for antineoplastic drug action. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology 1988. J. B. Lippincott, Philadelphia, p 65

    Google Scholar 

  21. Scheithauer W. Von Hoff DD, Clark GM, Shillis JL, Elslager EF (1986) In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol 22: 921

    Google Scholar 

  22. Spiridonidis CA, Chatterjee S, Petzold SJ (1989) Topoisomerase II-dependent and-independent mechanisms of etoposide resistance in Chinese hamster cell lines. Cancer Res 49: 644

    Google Scholar 

  23. Vries EGE de, Meijer C, Timmer-Bosscha H, Berendsen HH, Leij L de, Scheper RJ, Mulder NH (1989) Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res 49: 4175

    Google Scholar 

  24. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665

    Google Scholar 

  25. Zijlstra JG, Vries EGE de, Mulder NH (1987) Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780

    Google Scholar 

  26. Zijlstra JG, Jong S de, Vries EGE de, Mulder NH (1990) Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7: 11

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, P. O. 30.001, 9700 RB, Groningen, The Netherlands

    Steven de Jong, Jan G. Zijlstra, Nanno H. Mulder & Elisabeth G. E. de Vries

Authors
  1. Steven de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan G. Zijlstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nanno H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth G. E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by Dutch Cancer Foundation grants GUKC 90-18 and 91-08

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Jong, S., Zijlstra, J.G., Mulder, N.H. et al. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother. Pharmacol. 28, 461–464 (1991). https://doi.org/10.1007/BF00685823

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685823

Keywords

Search

Navigation